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Background and Purpose: The computed tomography (CT) angiography or 
contrast-enhanced CT based 'spot sign' has been proposed as a biomarker for 
identifying on-going hematoma expansion in patients with acute intracerebral 
hemorrhage. We investigated, if spot-sign positive participants benefit more from 
tranexamic acid versus placebo as compared to spot-sign negative participants.   
 
Methods: Tranexamic Acid for Intracerebral Haemorrhage (TICH-2) trial was a 
randomized, placebo-controlled clinical trial recruiting acutely hospitalized 
participants with intracerebral hemorrhage within 8 hours after symptom onset. Local 
investigators randomized participants to 2 grams of intravenous tranexamic acid or 
matching placebo (1:1). All participants underwent CT-scan on admission and on day 
2 (24 hours ±12 hours) after randomization. In this sub-group analysis, we included 
all participants from the main trial population with imaging allowing adjudication of 
spot sign status.  
 
Results: Of the 2325 TICH-2 participants, 254 (10.9%) had imaging allowing for 
spot-sign adjudication. Of these participants, 64 (25.2%) were spot-sign positive. 
Median (IQR) time from symptom onset to administration of the intervention was 
225.0 (169.0 to 310.0) minutes. The adjusted percent difference in absolute day-2 
hematoma volume between participants allocated to tranexamic versus placebo was 
3.7% (95% CI -12.8% to 23.4%) for spot-sign positive and 1.7% (95% CI -8.4% to 




observed in significant hematoma progression (dichotomous composite outcome) 
between participants allocated to tranexamic versus placebo among spot-sign 
positive (OR 0.85; 95% CI 0.29 to2.46) and negative (OR 0.77; 95% CI 0.41 to 1.45) 
participants (pheterogenity=0.88).  
 
Conclusions: Data from the TICH-2 trial do not support that admission spot sign 
status modifies the treatment effect of tranexamic acid versus placebo in patients 
with acute intracerebral hemorrhage. The results might have been affected by low 
statistical power as well as treatment delay. 
 
Clinical trial registration: Clinical Trial Registration-URL: http://www.controlled-
trials.com. Unique identifier: ISRCTN93732214. 
 
Non-standard Abbreviations and Acronyms 
CTA – CT-angiography 
CECT – contrast-enhanced CT 
IMP – Investigational medicinal product (IMP) 
APD – adjusted percent difference 










Intraparenchymal hematoma expansion is widely recognized as a target for 
therapeutic interventions aiming at improving the outcome in patients with 
spontaneous intracerebral hemorrhage.1 Recent studies have indicated that the risk 
of hematoma expansion is greatest during the first hours after symptom onset and 
gradually decreases during the first 24 hours.2,3 Hematoma expansion is known to 
occur after hospital admission in about 30% of acute intracerebral hemorrhage 
patients2 and has been causally linked to neurological deterioration during 
admission,4 early mortality, and poor functional outcome at 90 days.5  
 
In the Tranexamic Acid for Hyperacute Intracerebral Haemorrhage  (TICH-2) Trial 
(published in 2018),6 as well as in previous trials randomizing anticoagulation-naïve 
participants with acute spontaneous intracerebral hemorrhage to hemostatic agents 
versus placebo,7,8 it has been shown that while hematoma expansion could be 
limited to some extent, improvement in day-90 functional outcome has not yet been 
demonstrated. As previous trials have not been able to demonstrate that 
administration of hemostatic agents improve functional outcome in a relatively wide 
selection of participants with intracerebral hemorrhage, selective administration of 
hemostatic agents to participants at a high risk of hematoma expansion has been 
suggested.9 The hypothesis behind this proposal being that only patients with 





One, repeatedly proposed biomarker for hematoma expansion is the 'spot sign' on 
CT-angiography or contrast-enhanced CT. The spot sign is assumed to represent 
active leakage of contrast-enriched blood into the hematoma10,11 and has in several 
independent studies been found to be a powerful predictor of hematoma 
expansion.10,12 As spot-sign positive patients are believed to harbor on-going 
hematoma expansion, it has been hypothesized that these patients would experience 
a greater benefit from administration of hemostatic agents compared to spot-sign 
negative patients. To date, three smaller clinical trials have randomized spot-sign 
positive participants to hemostatic agents versus placebo. Unfortunately, overall 
neutral results on the prevention of hematoma expansion have been presented.13,14 
In this pre-specified TICH-2 subgroup analysis, we aimed to investigate, whether 
participants with a spot sign on admission scan would experience greater benefit 
from acute administration of tranexamic acid versus placebo compared to spot-sign 
negative participants.  
 
Materials and methods 
 
This study is a prespecified subgroup analysis of the TICH-2 trial. Before locking the 
main TICH-2 trial database, a statistical analysis plan for this subgroup analysis was 
submitted for publication.15 The design, statistical analysis, and main results of the 
TICH-2 trial have previously been published.6,16-18 In short, the TICH-2 trial was a 
pragmatic, randomized, parallel, placebo-controlled, phase III clinical trial powered to 
assess the hypothesis that administration of 2 grams of tranexamic acid versus 




presumed spontaneous intracerebral hemorrhage within eight hours after symptom 





The complete list of inclusion and exclusion criteria has previously been published.18 
Informed consent was obtained in accordance with national legislation. After 
publication of the pre-planned primary and secondary analyses, the deidentified 
individual participant trial data, accompanying meta-data and statistical analytic code 
can be shared upon reasonable request to the corresponding author and the TICH-2 
Trial steering committee. 
  
In the present subgroup analysis, we included all participants from the TICH-2 main 
trial population having either CT-angiography or contrast-enhanced CT performed 
before administration of the first dose of the investigational medicinal product (IMP). 
No constraints regarding scanner settings or radiological scanning protocol for the 
CT-angiography or contrast-enhanced CT were imposed, but the scanning needed to 
cover the entire hematoma, and the qualifying scan had to be available for central 
spot sign adjudication. CT-angiography or contrast-enhanced CT not covering the 
entire hematoma were accepted, if a spot sign fulfilling the definition below was 





After 24 hours (±12 hours), the participant underwent day-2 non-contrast CT and 
physical examination (NIHSS and GCS). All serious adverse events, as defined by 
the International Conference on Harmonization Guideline for Good Clinical 
Practice,16,18 were reported by local investigators until day seven after randomization. 
Predefined safety events (death, thromboembolism [arterial and venous], or seizures) 
were reported until day 90. At day 90, a telephone or postal interview was conducted 
assessing mortality status, safety outcomes after discharge, and functional outcome 
(modified Rankin Scale and Barthel Index).  
 
Two central adjudicators (CO and RD) independently adjudicated CT-angiograms 
and contrast-enhanced CTs for presence of a spot sign. Differences were resolved 
by discussion. The trial database had been unblinded at the time of spot sign 
adjudication, but the two central adjudicators were blinded to treatment allocation of 
the participants during spot sign adjudication sessions.  
 
On CT-angiography, we defined the spot sign as at least one element with either 
serpiginous and/or spot-like appearance, > 1.5 mm in diameter (maximal dimension), 
at least double density (Hounsfield unit) compared to background hematoma, and 
located within the margin of the parenchymal hematoma without connection to 
outside vessels. 15,19 On contrast-enhanced CT (post-contrast sequence), we defined 
the spot sign as at least one hyperdensity (relative to the hematoma) within the 
hematoma indicative of contrast extravasation on post-contrast imaging (not present 
on pre-contrast CT).15,20 In addition local investigators were asked to report the 




local investigators were not asked to comply with any predefined definition of the spot 
sign. 
 
Blinded radiological assessment and volume measurements of admission and day-2 
CTs have previously been described.6 In short, the local sites were required to send 
the conducted radiological examinations to the trial office for blinded radiological 
adjudication. All hematoma volumes (intraventricular and intraparenchymal) were 
measured using semi-automated segmentation. The segmentation was carried out 
using the active contour tool in the ITK-SNAP software (version 3.6, 
www.itksnap.org). One of three assessors did manual controlling and editing of the 
contours to ensure the best fit to the segmented structure.6 Four non-contrast scans 





All participants were included in the primary outcome analysis, provided they had an 
unbiased day-2 CT performed within 24 hours ±12 hours after randomization. A 
biased CT was defined as a CT obtained after any surgical procedure potentially 
influencing either the intraparenchymal or intraventricular hematoma volume 
(radiological signs of surgery on CT). If no unbiased day-2 CT performed within the 
time-window was available, an unbiased CT obtained after randomization, but before 





The primary outcome was absolute day-2 intraparenchymal hematoma volume. We 
also analyzed the primary outcome as the combined day-2 intraparenchymal and 
intraventricular hematoma volume.  
 
The first secondary outcome included dichotomous hematoma progression defined 
as a composite of either intraparenchymal hematoma expansion (≥ 6mL absolute or 
33% relative expansion), delayed intraventricular or subarachnoid extension, or 
intraventricular hematoma expansion (≥ 2 mL absolute expansion).15 All the elements 
of the dichotomous hematoma progression outcome were evaluated on the day-2 CT 
with admission CT as reference. Delayed intraventricular or subarachnoid extension 
were defined as extension not present on admission CT – but supervened on day-2 
CT. If no unbiased day-2 CT or clinical scan were available, early neurological 
deterioration or death occurring between admission and day 2 were regarded as 
hematoma progression. Neurological deterioration was defined as either a ≥ 4 points 
NIHSS increase, a ≥ 2 points GCS decrease, or a decrease in neurological 
performance leading to intubation or neurosurgical intervention documented in a 
serious adverse event report.  
 
Other secondary outcomes included serious adverse events within the first seven 
days, safety events until day 90, thromboembolic events until day 90, poor functional 
outcome at day 90 (modified Rankin scale 4-6), Barthel index at day 90, and mortality 





Due to the heterogeneous methodology concerning CT-angiography and contrast-
enhanced CT among the local centers, we conducted the following sensitivity 
analyses according to the spot-sign status: (1) on CT-angiography only (excluding 




The final sample size of this subgroup analysis was determined by enrollment into 
the TICH-2 trial. We prospectively estimated that if 54 spot-sign positive participants 
were enrolled in the primary outcome analysis, a mean difference in follow-up 
hematoma volume between participants allocated to tranexamic acid versus placebo 
of 10 mL (standard deviation [SD] 17 mL) would yield a power of 84.4%.15 Interrater 
reliability was analyzed using Cohen’s kappa. In all outcome analyses, the relative 
intervention effect (tranexamic acid versus placebo) among spot-sign positive and 
negative participants respectively was calculated from a regression model containing 
spot-sign status (yes/no) and trial intervention as main effects in addition to the 
multiplicative interaction between the two. The heterogeneity of treatment effect 
between spot-sign positive and negative participants was judged by the statistical 
significance of the interaction term. We chose to adjust all outcome analyses for 
participant age, time from onset to randomization, and NIHSS, as these are important 
prognostic factors and are used as minimization factors during the allocation 
process.18 The primary outcome analysis was in addition to the previously mentioned 
covariates also adjusted for admission hematoma volume (admission 




volume analysis and combined admission intraparenchymal and intraventricular 
hematoma volume for the day-2 combined intraparenchymal and intraventricular 
hematoma volume analysis). As pre-planned in the statistical analysis plan, we chose 
to abstain from adjusting for all minimization or stratification factors due to the risk of 
overfitting.15 In the published statistical analysis plan, we inadvertently prespecified to 
adjust for time from onset to treatment, but chose to replace this with time from onset 
to randomization, as this covariate was used as minimization factor.15 We repeated 
all main analyses adjusting for time from onset to treatment, and the results were 
similar. The primary outcome was analyzed by linear regression, dichotomous 
secondary outcomes by logistic regression, and time-to-death by Cox proportional 
hazard model.15 As the dependent variable in the primary outcome analysis (day-2 
hematoma volume) was log-transformed (natural logarithm), parameters in the 
regression analysis were interpreted as adjusted percent difference in geometric 
means. We tested the model assumptions as specified in the analysis plan 
(Supplement F - please see https://www.ahajournals.org/journal/str).15 Due to the 
tendency for participants in clinical trials to cluster within stratification units (i.e. 
country), we conducted a sensitivity analysis taking clustering within countries into 
account by use of generalized estimating equations. All analyses were conducted as 
intention-to-treat analyses. We utilized a nominal statistical significance level of 5% in 








Of the total 2325 participants in the TICH-2 trial population, 254 (10.9%) participants 
from seven countries had a CT-angiography or a contrast-enhanced CT allowing spot 
sign adjudication (Supplementary Figure I - please see 
https://www.ahajournals.org/journal/str). The 254 participants were generally 
comparable to the rest of the TICH-2 population (Supplementary Table I - please 
see https://www.ahajournals.org/journal/str), but the median [interquartile range - 
IQR] time from onset to IMP administration was shorter among participants with CT-
angiography or contrast-enhanced CT compared to the rest of the TICH-2 population 
(225.0 [169.0 to 310.0] compared to 245.0 [180.0 to 334.0] minutes). 64 (25.2%) 
participants were spot-sign positive. Between the two central spot sign adjudicators 
(CO and RD), a good interrater agreement for spot sign on CT-angiography (, 0.82; 
95% CI 0.74 to 0.91) was observed. The agreement between the two central 
adjudicators and the investigators at the sites was fair (, 0.57, 95% CI 0.44 to 0.70). 
The overall median (IQR) delay from symptom onset to CT-angiography or contrast-
enhanced CT was 123.0 (89.0 to 190.0) minutes and from CT-angiography or 
contrast-enhanced CT to IMP administration 76.0 (57.0 to 118.0) minutes. The 
baseline data were generally well balanced between allocation groups within spot-
sign positive and negative participants (Table 1). However, spot-sign positive 
participants allocated to tranexamic acid had longer median [IQR] delay from 
symptom onset to IMP administration (210.0 [159.0 to 270.0] minutes versus 169.0 
[141.0 to 231.0] minutes), and larger mean [SD] admission hematoma volumes (46.0 





In total, 215 participants were available for analysis of the primary outcome (Figure 
1). Day-2 hematoma volume was comparable between spot-sign positive participants 
allocated to tranexamic acid versus placebo (adjusted percent difference [aPD], 
3.7%; 95% CI -12.8% to 23.4%). The same was true for spot-sign negative 
participants (aPD, 1.7%; 95% CI -8.4% to 12.8%) (pheterogeneity = 0.85). Looking at the 
combined intraparenchymal and intraventricular hematoma volumes, comparable 
results were observed with no statistically significant difference among spot-sign 
positive participants (aPD, 5.0%; 95% CI -12.2% to 25.6%) or spot-sign negative 
participants (aPD, 2.1%; 95% CI -8.3% to 13.8%) (pheterogeneity = 0.80). Absolute and 
relative expansion in hematoma volumes from admission to day-2 (or clinical scan) 
are available in supplementary material (Supplementary Table II - please see 
https://www.ahajournals.org/journal/str). The distribution of time from onset to CT-
angiography or contrast-enhanced CT against absolute hematoma expansion is 
presented in supplementary material (Supplementary Figure II - please see 
https://www.ahajournals.org/journal/str). A visual tendency can be observed 
towards participants experiencing major hematoma expansions also having short 
time from onset to CT-angiography or contrast-enhanced CT.  
 
We observed no difference in the odds of participants experiencing the composite 
hematoma progression outcome between allocation groups among spot-sign positive  
(adjusted odds ratio [aOR], 0.85; 95% CI 0.29 to 2.46) or spot-sign negative 
participants (aOR, 0.77; 95% CI 0.41 to 1.45) (pheterogeneity = 0.88) (Figure 2). When 
assessing the individual components of the composite outcome, no differences were 




sign positive or negative participants, respectively, with the exception of delayed 
intraventricular or subarachnoid hemorrhagic extension among spot-sign positive 
participants (aOR, 5.23; 95% CI 1.28 to 21.33) (Figure 2). 
 
During the first seven days, 144 serious adverse events occurred in 106 participants, 
and during the first 90 days, 88 safety events occurred in 73 participants. No 
statistically significant differences in the odds of serious adverse events, safety 
outcomes, or thromboembolic events between allocation groups among spot-sign 
positive or negative participants were observed (Supplementary Table III - please 
see https://www.ahajournals.org/journal/str). At day 90, one participant had been 
completely lost to follow-up and censured at discharge from hospital. No differences 
in modified Rankin Scale, Barthel Index, or survival were observed between the 
allocation groups among spot-sign positive or negative participants (Supplementary 
Table IV - please see https://www.ahajournals.org/journal/str). 
 
The sensitivity analyses of the CT-angiography-based spot sign alone or spot sign 
status as reported by the local investigators reached comparable results as those 
presented above (Supplementary Tables V to X - please see 
https://www.ahajournals.org/journal/str). The same was true for the sensitivity 
analysis taking clustering into account (Supplementary Tables XI to XIII - please 
see https://www.ahajournals.org/journal/str). In a post-hoc analysis of the spot 
signs predictive capability, we affirmed its ability to be an independent predictor of 




hematoma progression (aOR, 2.81; 95% CI 1.46 to 5.41) (Supplementary Table XIV 




In this pre-specified subgroup analysis of the TICH-2 trial, we were not able to 
demonstrate that the presence of a spot sign modified the treatment effect of 
tranexamic acid versus placebo. We were also not able to demonstrate that 
tranexamic acid could reduce the odds of hematoma progression among spot-sign 
positive or negative participants. These conclusions were robust when considering 
the CT-angiography-based spot sign alone and when the investigator reported spot 
sign was used. We further demonstrated that the spot sign can be reliably 
adjudicated and that the addition of advanced radiological imaging (CT-angiography 
and contrast-enhanced CT) was not associated with a longer time to IMP compared 
to the rest of the TICH-2 population.  
 
The primary limitation of this subgroup analysis is the low degree of statistical power 
due to the relatively few participants. This makes a firm conclusion of no treatment 
effect of tranexamic acid among spot-sign positive or negative participants 
premature.  
 
Another major limitation of this subgroup analysis is the fact that the overall median 
delay from CT-angiography or contrast-enhanced CT to administration of the IMP 




'snapshot' visualization of an ongoing bleeding episode.11 Since hematoma 
expansion is likely to be a multifactorial process driven by factors such as admission 
hematoma size,2 blood pressure,21 and coagulation disturbances,2 it is difficult to 
predict how long this ongoing bleeding episode will continue after demonstration of 
the spot sign. An immediate administration of tranexamic acid, after demonstration of 
the spot sign, would consequently yield the greatest theoretical benefit. This delay 
between qualifying imaging and administration of the hemostatic agent was also 
observed in the SPOTLIGHT and STOP-IT trials, and when contemplating the neutral 
results of these trials it is important to include the possibility that the relative 
extensive treatment delay (~70 minutes) between baseline CT and IMP-
administration might have influenced the ability of the IMP to limit hematoma 
expansion.13 
 
In addition to the delay from CT-angiography or contrast-enhanced CT to 
administration of the IMP, we also observed a relative long overall treatment delay 
from symptom onset to administration of the IMP. The overall median delay from 
symptom onset to administration of the IMP was 225 minutes. It is possible that this 
treatment delay was too extensive as the probability of hematoma expansion has 
been proposed to decrease rapidly within the first hours after symptom onset.2 This is 
supported by a post-hoc analysis from the FAST trial indicating an enhanced 
treatment benefit, if time to treatment is below 150 minutes9, as well as data from the 
STOP-AUST trial14 where administration of tranexamic acid versus placebo to spot-
sign positive participants within 3 hours after symptom onset was associated with a 




hours. In the STOP-AUST trial, the importance of short duration between symptom 
onset and administration of the hemostatic agent was further emphasized by a post-
hoc analysis of participants receiving treatment within 2 hours after symptom onset 
which demonstrated an impressively small, but non-significant, odds ratio towards 
hematoma expansion.14 The importance of early treatment is further supported by the 
data from the CRASH-3 trial demonstrating efficacy of tranexamic acid among 
participants with mild to moderate traumatic brain injury when treated within 3 
hours.22  
 
A further limitation of the present subgroup analysis is the possible heterogeneity of 
the CT-angiography protocols employed at the different local sites. The CT-
angiograms obtained in the TICH-2 centers were predominantly single-pass scans, 
and no constraints were imposed on the scanning protocol or scanner settings, which 
might have impacted the detection of the spot sign. Previous studies have indicated 
that especially the contrast-phase, during which the CT-angiography has been 
obtained,23,24 can affect the spot sign prevalence and its predictive capability. 
 
We observed statistically significant higher odds of delayed intraventricular or 
subarachnoid hemorrhagic extension among spot-sign positive participants allocated 
to tranexamic acid compared with placebo. This finding is difficult to explain, and it is 
likely that this is a chance finding owing to the relatively low numbers of events and 





Our present study has several strengths. First, our methodology was predefined in 
detail and published before the analysis began.15 Furthermore, both spot-sign 
positive and negative participants were treated within the same trial protocol. This 
allows us to directly compare benefits and risks of tranexamic acid between spot-sign 
positive and negative participants. Another important strength is that the population 
undergoing CT-angiography or contrast-enhanced CT did not seem to be vastly 
different from the rest of the TICH-2 population. The good interrater agreement 
between the central adjudicators of the spot sign is encouraging, as it demonstrates 
its reproducible nature. Previous studies have reported heterogeneous interrater 
agreements varying with study setting and experience of the observers.12,25,26  
 
Although our subgroup analysis is limited by low statistical power, the results 
presented in this article could be used to promote further hypothesis generation. It is 
our hope that this study can be used in comparisons and meta-analyses with other 




In this TICH-2 subgroup analysis, we were not able to demonstrate that the presence 
of a spot sign modified the treatment effect of tranexamic acid versus placebo. The 
results might, however, have been affected by low statistical power as well as 
treatment delay. Further research is needed to determine the role of the spot sign in 
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Table 1: Baseline characteristics  
 










Age, years 66.5 (14.9)  63.1 (14.4)  65.8 (14.1) 61.2 (13.2)  
Sex, male 19 (63.3%) 18 (52.9%) 56 (58.9%) 60 (63.2%) 
Ethnic origin 
   
White 27 (90.0%) 27 (79.4%) 73 (76.8%) 77 (81.1%) 
Other 3 (10.0%) 7 (20.6%) 22 (23.2%) 18 (18.9%) 
Onset to CTA or CECT, minutes  107.0 (88.0-155.0) 100.0 (68.0-134.0)  143.0 (99.0-237.0)  124.0 (92.0-201.0)  







Onset to IMP administration, 







≤ 3 hours 12 (41.4%) 20 (58.8%) 24 (25.3%) 25 (26.3%) 
≤ 4.5 hours 22 (75.9%) 28 (82.4%) 53 (55.8%) 57 (60.0%) 
CTA or CECT to IMP 
administration, minutes 72.0 (44.0-131.0)  61.0 (42.0-111.0)  90.0 (57.0-125.0)  76.0 (63.0-116.0)  
Antiplatelet therapy on admission 9 (30.0%) 8 (23.5%) 25 (26.3%) 16 (16.8%) 
Statin therapy on admission 4 (13.8%) 9 (27.3%) 25 (26.6%) 18 (19.1%) 
History of ischemic stroke or TIA 4 (13.3%) 4 (12.1%) 10 (10.6%) 8 (8.6%) 
History of ischemic heart disease 2 (6.9%) 3 (9.1%) 10 (10.8%) 6 (6.5%) 
History of thromboembolism 0 (0%) 0 (0%) 2 (2.2%) 1 (1.1%) 
Pre-stroke modified Rankin scale 0.0 (0.0-1.0) 0.0 (0.0-0.0)  0.0 (0.0-1.0)  0.0 (0.0-0.0)  
Admission GCS score 14.0 (10.0-15.0)  15.0 (11.0-15.0)  15.0 (13.0-15.0)  15.0 (13.0-15.0)  
Admission NIHSS score 18.0 (14.0-19.0)  16.5 (11.0-21.0)  10.0 (6.0-16.0)  10.0 (5.0-18.0) 
Systolic blood pressure, mmHg 172.8 (30.9)  178.9 (31.5)  171.7 (25.6)  180.0 (32.7)  
Diastolic blood pressure, mmHg 93.4 (17.7)  97.6 (21.8)  93.3 (16.6)  98.7 (19.6)  
Hematoma location 




- Supratentorial lobar 12 (40.0%) 12 (35.3%) 30 (31.6%) 20 (21.1%) 
- Supratentorial deep 16 (53.3%) 20 (58.8%) 55 (57.9%) 64 (67.4%) 
- Infratentorial 2 (6.7%) 1 (2.9%) 7 (7.4%) 8 (8.4%) 
- Combination 0 (0%) 1 (2.9%) 3 (3.2%) 3 (3.2%) 
Admission intraparenchymal 
hematoma volume, mL 46.0 (31.9)  38.4 (27.6)  22.5 (25.8)  17.6 (21.4)  
Admission intraventricular 




volume, mL 50.5 (31.5)  42.9 (29.2)  24.8 (27.0)  19.6 (23.1)  
Admission subarachnoid 
hemorrhagic extension 5 (16.7%) 7 (20.6%) 14 (14.7%) 6 (6.3%) 
Data are mean (SD), median (IQR) or number (%). CTA – CT-angiography, CECT – contrast-enhanced CT, IMP 
– investigational medicinal product, TIA – transient ischemic attack, GCS – Glasgow Coma Scale, NIHSS – 












Figure 1: Figure is showing the primary outcome analyses expressed as the adjusted percent 
difference between allocation groups. *Treatment effect adjusted for admission hematoma volume, 
age (<70 compared to 70 years), time from onset to randomization (< 3 compared to  3 hours) and 
National Institute of Health Stroke Scale (< 15 compared to  15 points). SD – standard deviation, no. 
– number of participants, aPD – adjusted percent difference, CI – confidence interval, CT – computed 
tomography, mL – milliliter.  
 
 
Figure 2: Figure is showing the secondary hematoma progression outcome measure and its 
components. *Treatment effect adjusted for admission hematoma volume, age (< 70 compared to  70 
years), time from onset to randomization (< 3 compared to  3 hours) and National Institute of Health 
Stroke Scale (< 15 compared to  15 points). CT – computed tomography, mL – milliliter, OR – odds 
ratio, no. – number of participants, CI – confidence interval. 
 
 
 
